• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Insiders Buying Westlake Chemical Partners And 2 Other Stocks

    4/2/24 9:06:23 AM ET
    $ONCT
    $WLKP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Chemicals
    Industrials
    Get the next $ONCT alert in real time by email

    Although U.S. stocks closed mostly lower on Monday, there were a few notable insider trades.

    When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

    Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

    Sow Good

    • The Trade: Sow Good Inc. (OTC:SOWG) Director Lyle Berman acquired a total of 68,966 shares an average price of $7.25. To acquire these shares, it cost around $500,004.
    • What’s Happening: On March 28, Sow Good announced a $3.7 million private placement.
    • What Sow Good Does: Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups.

    Oncternal Therapeutics

    • The Trade: Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Director Robert James Wills acquired a total of 6,914 shares at an average price of $8.48. To acquire these shares, it cost around $58,602.
    • What’s Happening: On March 7, Oncternal Therapeutics posted upbeat quarterly sales.
    • What Oncternal Therapeutics Does: Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need.

    Don’t forget to check out our premarket coverage here

    Westlake Chemical Partners

    • The Trade: Westlake Chemical Partners LP (NYSE:WLKP) SVP, Olefin Material & Corp Pr Andrew Kenner bought a total of 5,000 shares at an average price of $22.23. To acquire these shares, it cost around $111,150.
    • What’s Happening: On Feb. 20, Westlake Chemical posted downbeat quarterly results.
    • What Westlake Chemical Partners Does: Westlake Chemical Partners LP is a part of the chemical industry in the United States.

     

    Check This Out: Dave & Buster's Likely To Report Higher Q4 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

    Get the next $ONCT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ONCT
    $WLKP

    CompanyDatePrice TargetRatingAnalyst
    Westlake Chemical Partners LP
    $WLKP
    3/2/2022$30.00 → $31.00Buy
    Deutsche Bank
    Oncternal Therapeutics Inc.
    $ONCT
    2/24/2022$5.00Buy
    BTIG
    Oncternal Therapeutics Inc.
    $ONCT
    2/24/2022$50.00Buy
    BTIG
    Westlake Chemical Partners LP
    $WLKP
    7/16/2021$27.00Buy → Underperform
    BofA Securities
    More analyst ratings

    $ONCT
    $WLKP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Gilson Jean-Marc bought $22,830 worth of Common Units (1,000 units at $22.83), increasing direct ownership by 34% to 3,927 units (SEC Form 4)

      4 - Westlake Chemical Partners LP (0001604665) (Issuer)

      9/3/24 9:39:37 AM ET
      $WLKP
      Major Chemicals
      Industrials
    • President and CEO Gilson Jean-Marc bought $45,842 worth of Common Units (2,000 units at $22.92), increasing direct ownership by 216% to 2,927 units (SEC Form 4)

      4 - Westlake Chemical Partners LP (0001604665) (Issuer)

      8/28/24 5:25:29 PM ET
      $WLKP
      Major Chemicals
      Industrials
    • President and CEO Gilson Jean-Marc bought $21,090 worth of Common Units (927 units at $22.75) (SEC Form 4)

      4 - Westlake Chemical Partners LP (0001604665) (Issuer)

      8/26/24 9:40:16 AM ET
      $WLKP
      Major Chemicals
      Industrials

    $ONCT
    $WLKP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations

      SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. today announced the sale of its zilovertamab and ONCT-808 programs to Ho'ola Therapeutics, Inc. Zilovertamab is an investigational monoclonal antibody designed to inhibit the function of Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1), and ONCT-808 is an investigational autologous chimeric antigen receptor T (CAR T) cell therapy that targets ROR1 using the binding domain from zilovertamab. Ho'ola will pay Oncternal a $3.0 million upfront payment, with $2.25 million paid immediately and $750,000 upon resolution of certain outstanding contractual obligations with third parties. Oncternal will also be eligible t

      7/1/25 8:00:00 AM ET
      $ONCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Westlake Chemical Partners LP Announces First Quarter 2025 Results

      Declared quarterly distribution of $0.4714 per unit; 43rd consecutive quarterly distribution Westlake Chemical Partners LP (NYSE:WLKP) (the "Partnership") today reported net income attributable to the Partnership in the first quarter of 2025 of $4.9 million, or $0.14 per limited partner unit, which was below first quarter 2024 net income of $14.8 million. Cash flows from operating activities in the first quarter of 2025 were $45.8 million, a decrease of $58.8 million compared to first quarter 2024 cash flows from operating activities of $104.6 million, due to lower production and sales volume as the result of the planned Petro 1 turnaround. For the three months ended March 31, 2025, MLP

      5/2/25 6:30:00 AM ET
      $WLKP
      Major Chemicals
      Industrials
    • Westlake Chemical Partners LP Announces First Quarter 2025 Distribution

      $0.4714 per unit distribution declared payable on May 29, 2025 The Board of Directors of Westlake Chemical Partners GP LLC, the general partner of Westlake Chemical Partners LP (the "Partnership") (NYSE:WLKP), has declared a distribution of $0.4714 per unit. This is the 43rd quarterly distribution announced by the Partnership since its initial public offering. The distribution will be payable on May 29, 2025, to unit holders of record on May 13, 2025. This release is intended to be a qualified notice under Treasury Regulation Section 1.1446-4(b). Brokers and nominees should treat one hundred percent (100.0%) of the Partnership's distributions to non-U.S. investors as being attributable

      4/30/25 4:15:00 PM ET
      $WLKP
      Major Chemicals
      Industrials

    $ONCT
    $WLKP
    SEC Filings

    See more
    • SEC Form 144 filed by Westlake Chemical Partners LP

      144 - Westlake Chemical Partners LP (0001604665) (Subject)

      5/27/25 5:28:46 PM ET
      $WLKP
      Major Chemicals
      Industrials
    • Amendment: SEC Form SCHEDULE 13G/A filed by Westlake Chemical Partners LP

      SCHEDULE 13G/A - Westlake Chemical Partners LP (0001604665) (Subject)

      5/15/25 3:00:27 PM ET
      $WLKP
      Major Chemicals
      Industrials
    • SEC Form 10-Q filed by Westlake Chemical Partners LP

      10-Q - Westlake Chemical Partners LP (0001604665) (Filer)

      5/2/25 3:18:59 PM ET
      $WLKP
      Major Chemicals
      Industrials

    $ONCT
    $WLKP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Senior Chairman Chao James sold $81,770 worth of Common Units (3,700 units at $22.10), closing all direct ownership in the company (SEC Form 4)

      4 - Westlake Chemical Partners LP (0001604665) (Issuer)

      5/30/25 9:16:27 AM ET
      $WLKP
      Major Chemicals
      Industrials
    • Senior Chairman Chao James sold $225,989 worth of Common Units (10,208 units at $22.14), decreasing direct ownership by 73% to 3,700 units (SEC Form 4)

      4 - Westlake Chemical Partners LP (0001604665) (Issuer)

      5/29/25 12:17:08 PM ET
      $WLKP
      Major Chemicals
      Industrials
    • President and CEO Gilson Jean-Marc bought $22,830 worth of Common Units (1,000 units at $22.83), increasing direct ownership by 34% to 3,927 units (SEC Form 4)

      4 - Westlake Chemical Partners LP (0001604665) (Issuer)

      9/3/24 9:39:37 AM ET
      $WLKP
      Major Chemicals
      Industrials

    $ONCT
    $WLKP
    Leadership Updates

    Live Leadership Updates

    See more
    • Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

      Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc.

      4/10/25 8:30:00 AM ET
      $ACOG
      $CBAY
      $MIST
      $ONCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

      SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Anne C. Hansen, who is joining Oncternal as Senior Director, Clinical Data Management. The award will be made on May 1, 2024 under Oncternal's 2021 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Oncternal as an inducement to join the Company. The award will consist of an option to purchase 5,000 shares of Oncternal common stock. The option will have a 10-year term

      5/1/24 9:00:00 AM ET
      $ONCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer

      SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced it will participate in a virtual fireside chat on the Treatment Landscape & New Treatment Options for Prostate Cancer. Oncternal's President and CEO, James Breitmeyer, M.D., Ph.D. will join Oppenheimer Senior Research Biotech Analyst, Hartaj Singh and a prostate cancer Key Opinion Leader on Tuesday, March 19th, 2024 at 11:00 AM ET. Dr. Breitmeyer will discuss the development of Oncternal's novel dual-acting androgen receptor inhibitor, ONCT-534, the ongoing Phase 1/2 clinical trial ONC

      3/15/24 9:00:00 AM ET
      $ONCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONCT
    $WLKP
    Financials

    Live finance-specific insights

    See more
    • Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations

      SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. today announced the sale of its zilovertamab and ONCT-808 programs to Ho'ola Therapeutics, Inc. Zilovertamab is an investigational monoclonal antibody designed to inhibit the function of Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1), and ONCT-808 is an investigational autologous chimeric antigen receptor T (CAR T) cell therapy that targets ROR1 using the binding domain from zilovertamab. Ho'ola will pay Oncternal a $3.0 million upfront payment, with $2.25 million paid immediately and $750,000 upon resolution of certain outstanding contractual obligations with third parties. Oncternal will also be eligible t

      7/1/25 8:00:00 AM ET
      $ONCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Westlake Chemical Partners LP Announces First Quarter 2025 Results

      Declared quarterly distribution of $0.4714 per unit; 43rd consecutive quarterly distribution Westlake Chemical Partners LP (NYSE:WLKP) (the "Partnership") today reported net income attributable to the Partnership in the first quarter of 2025 of $4.9 million, or $0.14 per limited partner unit, which was below first quarter 2024 net income of $14.8 million. Cash flows from operating activities in the first quarter of 2025 were $45.8 million, a decrease of $58.8 million compared to first quarter 2024 cash flows from operating activities of $104.6 million, due to lower production and sales volume as the result of the planned Petro 1 turnaround. For the three months ended March 31, 2025, MLP

      5/2/25 6:30:00 AM ET
      $WLKP
      Major Chemicals
      Industrials
    • Westlake Chemical Partners Announce First Quarter 2025 Earnings Conference Call

      Westlake Chemical Partners (NYSE:WLKP) will release its first quarter 2025 earnings prior to the market opening on Friday, May 2, 2025. The company will host a conference call at 1:00 p.m. Eastern Time (12:00 p.m. Central Time) on the same day to discuss the earnings release. To access the conference by phone, it is necessary to pre-register at https://register-conf.media-server.com/register/BIad7a525913764db1947af294b63227bb. Once registered, you will receive a phone number and unique PIN number. When you dial in, you will input the PIN number to be placed into the call. The conference call and replay will be available via webcast at https://edge.media-server.com/mmc/p/4889g59e and the e

      4/17/25 8:00:00 AM ET
      $WLKP
      Major Chemicals
      Industrials

    $ONCT
    $WLKP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Westlake Chemical Partners LP (Amendment)

      SC 13D/A - Westlake Chemical Partners LP (0001604665) (Subject)

      2/14/24 4:19:23 PM ET
      $WLKP
      Major Chemicals
      Industrials
    • SEC Form SC 13G/A filed by Westlake Chemical Partners LP (Amendment)

      SC 13G/A - Westlake Chemical Partners LP (0001604665) (Subject)

      2/14/24 2:02:09 PM ET
      $WLKP
      Major Chemicals
      Industrials
    • SEC Form SC 13G/A filed by Westlake Chemical Partners LP (Amendment)

      SC 13G/A - Westlake Chemical Partners LP (0001604665) (Subject)

      2/12/24 4:43:59 PM ET
      $WLKP
      Major Chemicals
      Industrials

    $ONCT
    $WLKP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Deutsche Bank reiterated coverage on Westlake Chemical with a new price target

      Deutsche Bank reiterated coverage of Westlake Chemical with a rating of Buy and set a new price target of $31.00 from $30.00 previously

      3/2/22 9:14:17 AM ET
      $WLKP
      Major Chemicals
      Industrials
    • BTIG initiated coverage on Oncternal Therapeutics with a new price target

      BTIG initiated coverage of Oncternal Therapeutics with a rating of Buy and set a new price target of $5.00

      2/24/22 7:15:03 AM ET
      $ONCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG initiated coverage on Oncternal Therapeutics with a new price target

      BTIG initiated coverage of Oncternal Therapeutics with a rating of Buy and set a new price target of $50.00

      2/24/22 7:15:03 AM ET
      $ONCT
      Biotechnology: Pharmaceutical Preparations
      Health Care